April 28, 2015
Daiichi Sankyo said on April 27 that its oral anticoagulant agent Lixiana (edoxaban), a selective factor Xa inhibitor, has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...read more